Artikel ; Online: Eficacia de infiltración intratimpánica de N-acetilcisteína en ototoxicidad por cisplatino.
Revista medica del Instituto Mexicano del Seguro Social
2023 Band 61, Heft Suppl 2, Seite(n) S318–S322
Abstract: Introduction: Currently there is no approved preventive or therapeutic pharmacological treatment to treat ototoxicity caused by cisplatin. N-acetyl cysteine (NAC) is a safe and inexpensive antioxidant that has been studied as an otoprotective ... ...
| Titelübersetzung | Efficacy of intratympanic infiltration of N-acetyl cysteine in cisplatin ototoxicity. | |||||
|---|---|---|---|---|---|---|
| Abstract | Introduction: Currently there is no approved preventive or therapeutic pharmacological treatment to treat ototoxicity caused by cisplatin. N-acetyl cysteine (NAC) is a safe and inexpensive antioxidant that has been studied as an otoprotective alternative. Objective: To describe the efficacy of intratympanic infiltration of NAC as prevention and treatment of ototoxicity induced in patients treated with cisplatin. Material and methods: Open, longitudinal, prospective, randomized clinical trial in cancer patients treated with cisplatin who met the inclusion criteria. Out of the sample of 22 patients, 11 underwent intratympanic NAC infiltration and 11 were taken as a control group. It was performed an audiometry at the beginning and one month after on all patients. Results: A sample of 22 patients with a mean age of 53 (±13) was collected. In our sample of 11 patients with infiltration in both ears, 1 ear showed improvement; on the other hand, in the control group that was not infiltrated, 4 showed an increase in hearing loss from mild to moderate in all 4 cases, 2 in the left ear and 2 in the right ear (Spearman's Rho = 0.93, p ≤ 0.001). Relative risk was of 1.22. Conclusions: An association can be observed that intratympanic NAC could become an alternative for the prevention and treatment of cisplatin-induced ototoxicity. |
|||||
| Mesh-Begriff(e) | Humans ; Middle Aged ; Cisplatin/adverse effects ; Antineoplastic Agents/adverse effects ; Acetylcysteine/therapeutic use ; Acetylcysteine/pharmacology ; Ototoxicity ; Prospective Studies | |||||
| Chemische Substanzen | Cisplatin (Q20Q21Q62J) ; Antineoplastic Agents ; Acetylcysteine (WYQ7N0BPYC) | |||||
| Sprache | Spanisch | |||||
| Erscheinungsdatum | 2023-09-18 | |||||
| Erscheinungsland | Mexico | |||||
| Dokumenttyp | Randomized Controlled Trial ; Clinical Trial ; English Abstract ; Journal Article | |||||
| ZDB-ID | 732133-8 | |||||
| ISSN | 2448-5667 ; 0443-5117 ; 0484-7849 | |||||
| ISSN (online) | 2448-5667 | |||||
| ISSN | 0443-5117 ; 0484-7849 | |||||
| Signatur |
|
|||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.B 2225: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.